February 16, 2022
Japan’s Ministry of Health, Labor and Welfare (MHLW) approved generics for 28 APIs (127 products) on February 15 towards the next biannual listing in June, giving the nod to authorized versions of multiple major brands such as Samsca (tolvaptan) and...read more